UNSPSC 51112511: Mafosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5970HH9923, chemically known as ethanesulfonic acid, 2-(((2r,4r)-2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)-, rel- but more generally known as mafosfamide, which bears US NIH Compound Identifier 104746. European Medicines Agency schedules Mafosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG.

UNSPSC 51112511 Mafosfamide is a Commodity code for a specific chemotherapy pharmaceutical agent. State and local governments procure this drug primarily through health and human services agencies, Medicaid programs, and institutional healthcare systems to support cancer treatment services. The Texas Health and Human Services Commission's April 2026 Request for Information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program illustrates the current procurement environment: states are exploring alternatives to traditional pharmacy benefit manager and group purchasing organization channels to source specialty pharmaceuticals directly from manufacturers, seeking improved cost management and prescription fulfillment efficiency. Solicitations under this code typically come from state health departments, Medicaid agencies, and centralized purchasing offices serving statewide health systems rather than municipal or county entities.

Activity under UNSPSC 51112511 is sparse in recent postings. The Texas HHS Commission's RFI represents the only documented recent state or local opportunity and signals a preliminary information-gathering phase rather than a formal competitive solicitation. The RFI closed on April 3, 2026, and sought vendor capabilities for direct manufacturer contracting outside traditional PBM and GPO structures, with focus on negotiated net pricing and value-based agreements. No award value, contract duration, or set-aside designations were identified in the RFI materials. The absence of additional recent opportunities under this code across other states or jurisdictions suggests limited active procurement volume at the state and local level for this specific pharmaceutical commodity, or that purchases are consolidated within larger pharmacy benefit or drug formulary contracts coded at a higher UNSPSC tier rather than at the individual-drug level.